Phase 3 Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have already taken part in a qualifying Phase 2 or Phase 3 study of the drug tulisokibart for Crohn's disease or ulcerative colitis
- Your doctor believes you are benefiting from continuing to take the study drug, based on how you have been doing in the previous study
- If you were born female, you are not breastfeeding during the study and for at least 14 weeks after your last dose
- If you could become pregnant, you have tested negative for pregnancy (via urine or blood test) within 24 or 72 hours before your first dose, depending on the type of test used
- If you could become pregnant, you agree to use an acceptable form of contraception, or you consistently abstain from penile-vaginal intercourse as part of your usual lifestyle
Who may not be able to join:
- You stopped taking the study drug early in your previous study (before you were supposed to finish)
- You took any medications during your previous study that were listed as not allowed under that study's rules
- You have a known allergy, sensitivity, or bad reaction to tulisokibart or any of its ingredients
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Phone: 1-888-577-8839
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants Who Experience an Adverse Event (AE); Number of Participants Who Discontinue Study Treatment Due to an AE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.